These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1391663)

  • 1. Preparation of genetically engineered monoclonal antibodies for human immunotherapy.
    Parren PW
    Hum Antibodies Hybridomas; 1992 Jul; 3(3):137-45. PubMed ID: 1391663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
    Werther WA; Gonzalez TN; O'Connor SJ; McCabe S; Chan B; Hotaling T; Champe M; Fox JA; Jardieu PM; Berman PW; Presta LG
    J Immunol; 1996 Dec; 157(11):4986-95. PubMed ID: 8943405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized antibodies as potential drugs for therapeutic use.
    Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
    Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable expression of cloned human antibody genes in murine myeloma cells.
    Knight DM; McDonough M; Moore MA; Abercrombie D; Siegel R; Ghrayeb J
    Hum Antibodies Hybridomas; 1992 Jul; 3(3):129-36. PubMed ID: 1391662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDR grafting--a new approach to antibody humanization.
    Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
    Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant antibodies.
    Larrick JW; Fry KE
    Hum Antibodies Hybridomas; 1991 Oct; 2(4):172-89. PubMed ID: 1751781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanisation of monoclonal antibodies for therapy.
    Gorman SD; Clark MR
    Semin Immunol; 1990 Nov; 2(6):457-66. PubMed ID: 2104282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antibodies by design.
    Vaughan TJ; Osbourn JK; Tempest PR
    Nat Biotechnol; 1998 Jun; 16(6):535-9. PubMed ID: 9624683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody.
    Graziano RF; Tempest PR; White P; Keler T; Deo Y; Ghebremariam H; Coleman K; Pfefferkorn LC; Fanger MW; Guyre PM
    J Immunol; 1995 Nov; 155(10):4996-5002. PubMed ID: 7594506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanization of chicken monoclonal antibody using phage-display system.
    Nishibori N; Horiuchi H; Furusawa S; Matsuda H
    Mol Immunol; 2006 Feb; 43(6):634-42. PubMed ID: 16360012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
    Scallon B; Cai A; Radewonuk J; Naso M
    Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering and characterization of a single-chain antibody fragment (scFV1924) against the human sarcoma-associated antigen p102.
    Chen H; Wang P; Das Gupta TK
    Anticancer Res; 2000; 20(4):2753-60. PubMed ID: 10953354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential.
    Looney JE; Knight DM; Arevalo-Moore M; Trinh H; Pak KY; Dalesandro MR; Rieber EP; Riethmuller G; Daddona PE; Ghrayeb J
    Hum Antibodies Hybridomas; 1992 Oct; 3(4):191-200. PubMed ID: 1477300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
    Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
    Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
    Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
    J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.